Skip to main content

CORRECTION article

Front. Immunol., 16 January 2024
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1365027

Corrigendum: Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager

This article is a correction to:

  1. Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager

    1. Read original article
Xinghui Xiao,Xinghui Xiao1,2Ying Cheng,Ying Cheng1,2Xiaodong Zheng,Xiaodong Zheng1,2Yuhang Fang,Yuhang Fang1,2Yu Zhang,Yu Zhang1,2Rui Sun,Rui Sun1,2Zhigang Tian,,*Zhigang Tian1,2,3*Haoyu Sun,*Haoyu Sun1,2*
  • 1Hefei National Research Center for Physical Sciences at Microscale, The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
  • 2Institute of Immunology, University of Science and Technology of China, Hefei, China
  • 3Hefei TG ImmunoPharma Corporation Limited, Hefei, China

A Corrigendum on
Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager

By Xiao X, Cheng Y, Zheng X, Fang Y, Zhang Y, Sun R, Tian Z and Sun H (2023) Front. Immunol. 14:1113303. doi: 10.3389/fimmu.2023.1113303

In the published article, there was an error in the funding statement for the National Key R&D Program of China (2019YFA0508502/3, 2018YFA0507403); Natural Science Foundation of China (8222053, 81972679); Natural Science Foundation of Anhui Province (2008085MH252). The correct Funding statement appears below.

Funding

This work was supported by the National Key R&D Program of China (2019YFA0508502/3, 2018YFA0507403); Natural Science Foundation of China (82222053, 81972679); Natural Science Foundation of Anhui Province (2008085MH252).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: NK-cell engager, T-cell engager, tumor immunotherapy, antitumor, proinflammatory cytokines

Citation: Xiao X, Cheng Y, Zheng X, Fang Y, Zhang Y, Sun R, Tian Z and Sun H (2024) Corrigendum: Bispecific NK-cell engager targeting BCMA elicits stronger antitumor effects and produces less proinflammatory cytokines than T-cell engager. Front. Immunol. 15:1365027. doi: 10.3389/fimmu.2024.1365027

Received: 03 January 2024; Accepted: 05 January 2024;
Published: 16 January 2024.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2024 Xiao, Cheng, Zheng, Fang, Zhang, Sun, Tian and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Haoyu Sun, aGFveXVzdW5AdXN0Yy5lZHUuY24=; Zhigang Tian, dHpnQHVzdGMuZWR1LmNu

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.